CeriBell (NASDAQ:CBLL) VP David Foehr Sells 862 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 862 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $18.80, for a total value of $16,205.60. Following the completion of the sale, the vice president owned 37,751 shares in the company, valued at $709,718.80. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Thursday, May 21st, David Foehr sold 987 shares of CeriBell stock. The stock was sold at an average price of $18.00, for a total value of $17,766.00.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The stock was sold at an average price of $17.80, for a total value of $81,168.00.

CeriBell Price Performance

NASDAQ:CBLL opened at $18.80 on Wednesday. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $713.27 million, a P/E ratio of -11.53 and a beta of 0.99. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33. The business’s 50-day moving average is $19.09 and its 200 day moving average is $19.24.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The firm had revenue of $26.49 million during the quarter, compared to analysts’ expectations of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. On average, equities research analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after acquiring an additional 147,013 shares during the last quarter. KCM Capital Inc increased its stake in CeriBell by 40.0% during the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock worth $25,662,000 after acquiring an additional 400,000 shares during the last quarter. Yu Fan increased its stake in CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after acquiring an additional 130,964 shares during the last quarter. Bank of New York Mellon Corp increased its stake in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after acquiring an additional 1,162,200 shares during the last quarter. Finally, Novo Holdings A S increased its stake in CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after acquiring an additional 20,000 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Canaccord Genuity Group decreased their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Finally, Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.